Takashi Fukuyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takashi Fukuyama has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Nobue Futawatari
11 shared publications- Hiroshi Nonoguchi
Division of Internal Medicine, Kitasato University Medical Center, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan
10 shared publications Hitoshi Yamazaki
Division of Pathology, Kitasato University Medical Centre, Kitamoto, Saitama, Japan
9 shared publicationsNoritada Kobayashi
Division of Biomedical Research, Kitasato University Medical Centre, Kitamoto, Saitama, Japan
9 shared publications- Noritada Kobayashi
Division of Biomedical Research, Kitasato University Medical Center, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan
9 shared publications - Taiga Yamazaki
Division of Biomedical Research, Kitasato University Medical Center, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan
9 shared publications
Latest Publications
- Open Access
KK-LC-1 reveals evolutionary divergence in the regulation of sperm motility between humans and mice
CT83 (KK-LC-1) is a cancer-testis antigen originally identified in human lung cancer cells and has recently attracted attention as a potential target for cancer therapy. Although KK-LC-1 orthologs have been identified in up to 160 animal species, a murine homolog had not previously been identified, hindering in vivo analysis of its physiological function. In this study, we identified the mouse homolog of KK-LC-1 and performed a comparative analysis of its properties in humans and mice, together with an investigation of its biological function using gene knockout (KO) mice. The murine Kk-lc-1 gene is located on the X chromosome and, like its human counterpart, contains an N-terminal transmembrane domain. In both humans and mice, KK-LC-1 is expressed specifically in the testis and localizes to the head and tail regions of sperm. Analysis of Kk-lc-1 -deficient mice revealed normal spermatogenesis, and both male and female KO mice were fertile. However, sperm from Kk-lc-1 -deficient males exhibited reduced motility caused by decreased flexibility of the midpiece and failed to penetrate the oocyte zona pellucida in vitro . This defect was rescued by artificial insemination using epididymal sperm, suggesting that maternal factors in vivo may compensate for reduced sperm motility. Although impaired sperm motility during in vitro fertilization (IVF) was rescued by murine Kk-lc-1 , functional rescue by human KK-LC-1 was not observed. These findings indicate that KK-LC-1 contributes to sperm motility but is not essential for fertility. Moreover, species-specific differences in KK-LC-1-mediated regulation of sperm motility suggest functional divergence during evolution. The role of KK-LC-1 in sperm motility should therefore be considered in the clinical development of cancer therapies targeting KK-LC-1.
Open AccessKK-LC-1 reveals evolutionary divergence in the regulation of sperm motility between humans and mice
CT83 (KK-LC-1) is a cancer-testis antigen originally identified in human lung cancer cells and has recently attracted attention as a potential target for cancer therapy. Although KK-LC-1 orthologs have been identified in up to 160 animal species, a murine homolog had not previously been identified, hindering in vivo analysis of its physiological function. In this study, we identified the mouse homolog of KK-LC-1 and performed a comparative analysis of its properties in humans and mice, together with an investigation of its biological function using gene knockout (KO) mice. The murine Kk-lc-1 gene is located on the X chromosome and, like its human counterpart, contains an N-terminal transmembrane domain. In both humans and mice, KK-LC-1 is expressed specifically in the testis and localizes to the head and tail regions of sperm. Analysis of Kk-lc-1 -deficient mice revealed normal spermatogenesis, and both male and female KO mice were fertile. However, sperm from Kk-lc-1 -deficient males exhibited reduced motility caused by decreased flexibility of the midpiece and failed to penetrate the oocyte zona pellucida in vitro . This defect was rescued by artificial insemination using epididymal sperm, suggesting that maternal factors in vivo may compensate for reduced sperm motility. Although impaired sperm motility during in vitro fertilization (IVF) was rescued by murine Kk-lc-1 , functional rescue by human KK-LC-1 was not observed. These findings indicate that KK-LC-1 contributes to sperm motility but is not essential for fertility. Moreover, species-specific differences in KK-LC-1-mediated regulation of sperm motility suggest functional divergence during evolution. The role of KK-LC-1 in sperm motility should therefore be considered in the clinical development of cancer therapies targeting KK-LC-1.
- Open Access
- 24 January 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 17 (1)
Kita-Kyushu lung cancer antigen-1 expression in initial gastric tumors predicts multiple cancer development: A pilot study
BACKGROUND We have previously reported that the cancer/testis antigen Kita-Kyushu lung cancer antigen-1 (KK-LC-1) is frequently expressed in gastric cancer (GC), with a particularly high positivity rate observed in patients with multiple GCs. Thus, we conducted a preliminary study to further investigate the relationship between KK-LC-1 expression and multiple GCs. Specifically, we aimed to explore the potential clinical utility of KK-LC-1 as a biomarker for identifying patients at risk of developing multiple gastric cancers, with a focus on its expression in the initial tumor lesions. AIM To investigate the association between KK-LC-1 expression and the development of multiple GCs in a preliminary cohort. METHODS Among 124 patients (177 lesions) treated for GC at Toho University Medical Center Ohashi Hospital between September 2020 and November 2023, 109 (single cancer: 82; multiple cancers: 27) with available initial tumor specimens were enrolled. KK-LC-1 expression was assessed using immunohistochemistry, and clinicopathological correlations were analyzed using Fisher’s exact test. Tumor locations were classified anatomically and analyses were performed, focusing on the initial cancer sites. RESULTS In tumors located in the upper stomach, KK-LC-1 expression did not correlate with clinicopathological features. However, in the middle and lower stomach, KK-LC-1 expression was significantly associated with older age, differentiated histological types, and multiple cancers. Notably, all patients with multiple GCs had KK-LC-1-positive tumors (100%) in their initial lesions. The KK-LC-1 positivity rate in the initial tumors of multiple cancers in the middle and lower region was significantly higher than that in solitary cancers. Conversely, the absence of KK-LC-1 expression in a solitary tumor located in the middle and lower region may suggest a reduced risk for the subsequent development of multiple primary cancers. CONCLUSION KK-LC-1 expression in the initial gastric tumors, particularly in the middle and lower stomach regions, may serve as a predictive biomarker for the future development of multiple GCs.
- 24 January 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 17 (1)
Open AccessKita-Kyushu lung cancer antigen-1 expression in initial gastric tumors predicts multiple cancer development: A pilot study
BACKGROUND We have previously reported that the cancer/testis antigen Kita-Kyushu lung cancer antigen-1 (KK-LC-1) is frequently expressed in gastric cancer (GC), with a particularly high positivity rate observed in patients with multiple GCs. Thus, we conducted a preliminary study to further investigate the relationship between KK-LC-1 expression and multiple GCs. Specifically, we aimed to explore the potential clinical utility of KK-LC-1 as a biomarker for identifying patients at risk of developing multiple gastric cancers, with a focus on its expression in the initial tumor lesions. AIM To investigate the association between KK-LC-1 expression and the development of multiple GCs in a preliminary cohort. METHODS Among 124 patients (177 lesions) treated for GC at Toho University Medical Center Ohashi Hospital between September 2020 and November 2023, 109 (single cancer: 82; multiple cancers: 27) with available initial tumor specimens were enrolled. KK-LC-1 expression was assessed using immunohistochemistry, and clinicopathological correlations were analyzed using Fisher’s exact test. Tumor locations were classified anatomically and analyses were performed, focusing on the initial cancer sites. RESULTS In tumors located in the upper stomach, KK-LC-1 expression did not correlate with clinicopathological features. However, in the middle and lower stomach, KK-LC-1 expression was significantly associated with older age, differentiated histological types, and multiple cancers. Notably, all patients with multiple GCs had KK-LC-1-positive tumors (100%) in their initial lesions. The KK-LC-1 positivity rate in the initial tumors of multiple cancers in the middle and lower region was significantly higher than that in solitary cancers. Conversely, the absence of KK-LC-1 expression in a solitary tumor located in the middle and lower region may suggest a reduced risk for the subsequent development of multiple primary cancers. CONCLUSION KK-LC-1 expression in the initial gastric tumors, particularly in the middle and lower stomach regions, may serve as a predictive biomarker for the future development of multiple GCs.
- Open Access
- 24 December 2025
- Published by Elsevier in Cellular Immunology
- Vol. 419, 105059
Functional and structural analysis of KK-LC-1-specific T cell receptors from patients with lung Cancer for immunotherapy
- 24 December 2025
- Published by Elsevier in Cellular Immunology
- Vol. 419, 105059
Open AccessFunctional and structural analysis of KK-LC-1-specific T cell receptors from patients with lung Cancer for immunotherapy
- 28 March 2025
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 45 (4) , 1599-1606
Association Between Kita-kyushu Lung Cancer Antigen-1 Expression in Gastric Cancer andHelicobacter pylori-infection Status
Background/Aim: Kita-kyushu lung cancer antigen-1 (KK-LC-1), a cancer/testis antigen (CTA), is frequently expressed in tumor and non-tumor sites of the stomach in patients with gastric cancer (GC). Additionally, KK-LC-1 has been associated with Helicobacter pylori (Hp) infection. Currently, the association between Hp eradication and GC incidence is unclear. This study aimed to investigate the association between KK-LC-1 expression and Hp eradication in GC. Patients and Methods: This study included 124 patients treated for gastric cancer. Pathological tissue from resected specimens was used to investigate KK-LC-1 expression in tumor and non-tumor sites. The association between 14 clinicopathological factors, including Hp infection and eradication, and KK-LC-1 expression was investigated and analyzed by Fisher’s exact test and multivariable regression analysis. Results: KK-LC-1 expression rate in cancerous tissues from patients with GC was 74.2%. The expression of KK-LC-1 was associated with older age, mucosal layer depth of invasion, differentiated type, no lymph node metastasis, Hp eradication, previous Hp infection, and multiple cancers. Conclusion: KK-LC-1 expression was high in GC cases with previous Hp infection and successful eradication. KK-LC-1 expression pattern suggests that it may be associated with GC independently of Hp infection.
- 28 March 2025
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 45 (4) , 1599-1606
Association Between Kita-kyushu Lung Cancer Antigen-1 Expression in Gastric Cancer andHelicobacter pylori-infection Status
Background/Aim: Kita-kyushu lung cancer antigen-1 (KK-LC-1), a cancer/testis antigen (CTA), is frequently expressed in tumor and non-tumor sites of the stomach in patients with gastric cancer (GC). Additionally, KK-LC-1 has been associated with Helicobacter pylori (Hp) infection. Currently, the association between Hp eradication and GC incidence is unclear. This study aimed to investigate the association between KK-LC-1 expression and Hp eradication in GC. Patients and Methods: This study included 124 patients treated for gastric cancer. Pathological tissue from resected specimens was used to investigate KK-LC-1 expression in tumor and non-tumor sites. The association between 14 clinicopathological factors, including Hp infection and eradication, and KK-LC-1 expression was investigated and analyzed by Fisher’s exact test and multivariable regression analysis. Results: KK-LC-1 expression rate in cancerous tissues from patients with GC was 74.2%. The expression of KK-LC-1 was associated with older age, mucosal layer depth of invasion, differentiated type, no lymph node metastasis, Hp eradication, previous Hp infection, and multiple cancers. Conclusion: KK-LC-1 expression was high in GC cases with previous Hp infection and successful eradication. KK-LC-1 expression pattern suggests that it may be associated with GC independently of Hp infection.
- Open Access
- 19 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 1223
Tubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury
Many large-scale studies show that exogenous erythropoietin, erythropoiesis-stimulating agents, lack any renoprotective effects. We investigated the effects of endogenous erythropoietin on renal function in kidney ischemic reperfusion injury (IRI) using the prolyl hydroxylase domain (PHD) inhibitor, Roxadustat (ROX). Four h of hypoxia (7% O2) and 4 h treatment by ROX prior to IRI did not improve renal function. In contrast, 24–72 h pretreatment by ROX significantly improved the decline of renal function caused by IRI. Hypoxia and 4 h ROX increased interstitial cells-derived Epo production by 75- and 6-fold, respectively, before IRI, and worked similarly to exogenous Epo. ROX treatment for 24–72 h increased Epo production during IRI by 9-fold. Immunohistochemistry revealed that 24 h ROX treatment induced Epo production in proximal and distal tubules and worked similarly to endogenous Epo. Our data show that tubular endogenous Epo production induced by 24–72 h ROX treatment results in renoprotection but peritubular exogenous Epo production by interstitial cells induced by hypoxia and 4 h ROX treatment did not. Stimulation of tubular, but not peritubular, Epo production may link to renoprotection.
- 19 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 1223
Open AccessTubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury
Many large-scale studies show that exogenous erythropoietin, erythropoiesis-stimulating agents, lack any renoprotective effects. We investigated the effects of endogenous erythropoietin on renal function in kidney ischemic reperfusion injury (IRI) using the prolyl hydroxylase domain (PHD) inhibitor, Roxadustat (ROX). Four h of hypoxia (7% O2) and 4 h treatment by ROX prior to IRI did not improve renal function. In contrast, 24–72 h pretreatment by ROX significantly improved the decline of renal function caused by IRI. Hypoxia and 4 h ROX increased interstitial cells-derived Epo production by 75- and 6-fold, respectively, before IRI, and worked similarly to exogenous Epo. ROX treatment for 24–72 h increased Epo production during IRI by 9-fold. Immunohistochemistry revealed that 24 h ROX treatment induced Epo production in proximal and distal tubules and worked similarly to endogenous Epo. Our data show that tubular endogenous Epo production induced by 24–72 h ROX treatment results in renoprotection but peritubular exogenous Epo production by interstitial cells induced by hypoxia and 4 h ROX treatment did not. Stimulation of tubular, but not peritubular, Epo production may link to renoprotection.
- Open Access
- 27 November 2023
- Published by MDPI AG in Preprints.org
Tubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury
Many large-scale studies revealed that exogenous erythropoietin, erythropoie-sis-stimulating agents, have no renoprotective effects. We investigated the effects of en-dogenous erythropoietin on renal function in ischemic reperfusion injury (IRI) of kidney using prolyl hydroxylase domaine (PHD) inhibitor, Roxadustat (ROX). 4 hr hypoxia (7% O2) and 4 hr treatment by ROX prior to IRI did not improve renal function. In contrast, 24-72 hr pre-treatment by ROX largely improved the decline of renal function by IRI. Hy-poxia and 4 hr ROX increased interstitial cells-derived Epo production by 75 and 6-fold, respectively, before IRI and worked as exogenous Epo. 24-72 hr ROX treatment increased Epo production during IRI by 9-fold. Immunohistochemistry revealed that 24 hr ROX caused Epo production in proximal and distal tubules and worked as endogenous Epo. Our data show that 24-72 hr ROX-induced tubular endogenous Epo production results in renoprotection but peritubular exogenous Epo production by interstitial cells-derived in-duced by hypoxia and 4 hr ROX did not. Stimulation of tubular but not peritubular Epo production may link to renoprotection.
- 27 November 2023
- Published by MDPI AG in Preprints.org
Open AccessTubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury
Many large-scale studies revealed that exogenous erythropoietin, erythropoie-sis-stimulating agents, have no renoprotective effects. We investigated the effects of en-dogenous erythropoietin on renal function in ischemic reperfusion injury (IRI) of kidney using prolyl hydroxylase domaine (PHD) inhibitor, Roxadustat (ROX). 4 hr hypoxia (7% O2) and 4 hr treatment by ROX prior to IRI did not improve renal function. In contrast, 24-72 hr pre-treatment by ROX largely improved the decline of renal function by IRI. Hy-poxia and 4 hr ROX increased interstitial cells-derived Epo production by 75 and 6-fold, respectively, before IRI and worked as exogenous Epo. 24-72 hr ROX treatment increased Epo production during IRI by 9-fold. Immunohistochemistry revealed that 24 hr ROX caused Epo production in proximal and distal tubules and worked as endogenous Epo. Our data show that 24-72 hr ROX-induced tubular endogenous Epo production results in renoprotection but peritubular exogenous Epo production by interstitial cells-derived in-duced by hypoxia and 4 hr ROX did not. Stimulation of tubular but not peritubular Epo production may link to renoprotection.
- Open Access
- 31 October 2022
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 13 (14) , 3526-3532
Detection of Kita-Kyushu Lung Cancer Antigen-1, a Cancer/Testis Antigen, in the Stomach Close to a Cancerous Condition
Background: Kita-Kyushu lung cancer antigen-1 (KK-LC-1), encoded by CT83, is a cancer/testis antigen (CTA) and an attractive target for immunotherapy. Our previous study demonstrated frequent CT83 expression in gastric cancers (GCs) and non-tumor sites of the stomach with tumors. Additionally, there was a correlation with Helicobacter pylori (Hp) infection. Since it currently remains unclear whether KK-LC-1 is expressed in the stomach without GC, this study investigated KK-LC-1 expression in non-GC stomach.
- 31 October 2022
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 13 (14) , 3526-3532
Open AccessDetection of Kita-Kyushu Lung Cancer Antigen-1, a Cancer/Testis Antigen, in the Stomach Close to a Cancerous Condition
Background: Kita-Kyushu lung cancer antigen-1 (KK-LC-1), encoded by CT83, is a cancer/testis antigen (CTA) and an attractive target for immunotherapy. Our previous study demonstrated frequent CT83 expression in gastric cancers (GCs) and non-tumor sites of the stomach with tumors. Additionally, there was a correlation with Helicobacter pylori (Hp) infection. Since it currently remains unclear whether KK-LC-1 is expressed in the stomach without GC, this study investigated KK-LC-1 expression in non-GC stomach.
- Open Access
Effects of Roxadustat on Erythropoietin Production in the Rat Body
Anemia is a major complication of chronic renal failure. To treat this anemia, prolylhydroxylase domain enzyme (PHD) inhibitors as well as erythropoiesis-stimulating agents (ESAs) have been used. Although PHD inhibitors rapidly stimulate erythropoietin (Epo) production, the precise sites of Epo production following the administration of these drugs have not been identified. We developed a novel method for the detection of the Epo protein that employs deglycosylation-coupled Western blotting. With protein deglycosylation, tissue Epo contents can be quantified over an extremely wide range. Using this method, we examined the effects of the PHD inhibitor, Roxadustat (ROX), and severe hypoxia on Epo production in various tissues in rats. We observed that ROX increased Epo mRNA expression in both the kidneys and liver. However, Epo protein was detected in the kidneys but not in the liver. Epo protein was also detected in the salivary glands, spleen, epididymis and ovaries. However, both PHD inhibitors (ROX) and severe hypoxia increased the Epo protein abundance only in the kidneys. These data show that, while Epo is produced in many tissues, PHD inhibitors as well as severe hypoxia regulate Epo production only in the kidneys.
Open AccessEffects of Roxadustat on Erythropoietin Production in the Rat Body
Anemia is a major complication of chronic renal failure. To treat this anemia, prolylhydroxylase domain enzyme (PHD) inhibitors as well as erythropoiesis-stimulating agents (ESAs) have been used. Although PHD inhibitors rapidly stimulate erythropoietin (Epo) production, the precise sites of Epo production following the administration of these drugs have not been identified. We developed a novel method for the detection of the Epo protein that employs deglycosylation-coupled Western blotting. With protein deglycosylation, tissue Epo contents can be quantified over an extremely wide range. Using this method, we examined the effects of the PHD inhibitor, Roxadustat (ROX), and severe hypoxia on Epo production in various tissues in rats. We observed that ROX increased Epo mRNA expression in both the kidneys and liver. However, Epo protein was detected in the kidneys but not in the liver. Epo protein was also detected in the salivary glands, spleen, epididymis and ovaries. However, both PHD inhibitors (ROX) and severe hypoxia increased the Epo protein abundance only in the kidneys. These data show that, while Epo is produced in many tissues, PHD inhibitors as well as severe hypoxia regulate Epo production only in the kidneys.
- Open Access
Effects of Angiotensin II on Erythropoietin Production in the Kidney and Liver
The kidney is a main site of erythropoietin production in the body. We developed a new method for the detection of Epo protein by deglycosylation-coupled Western blotting. Detection of deglycosylated Epo enables the examination of small changes in Epo production. Using this method, we investigated the effects of angiotensin II (ATII) on Epo production in the kidney. ATII stimulated the plasma Epo concentration; Epo, HIF2α, and PHD2 mRNA expression in nephron segments in the renal cortex and outer medulla; and Epo protein expression in the renal cortex. In situ hybridization and immunohistochemistry revealed that ATII stimulates Epo mRNA and protein expression not only in proximal tubules but also in collecting ducts, especially in intercalated cells. These data support the regulation of Epo production in the kidney by the renin–angiotensin–aldosterone system (RAS).
Open AccessEffects of Angiotensin II on Erythropoietin Production in the Kidney and Liver
The kidney is a main site of erythropoietin production in the body. We developed a new method for the detection of Epo protein by deglycosylation-coupled Western blotting. Detection of deglycosylated Epo enables the examination of small changes in Epo production. Using this method, we investigated the effects of angiotensin II (ATII) on Epo production in the kidney. ATII stimulated the plasma Epo concentration; Epo, HIF2α, and PHD2 mRNA expression in nephron segments in the renal cortex and outer medulla; and Epo protein expression in the renal cortex. In situ hybridization and immunohistochemistry revealed that ATII stimulates Epo mRNA and protein expression not only in proximal tubules but also in collecting ducts, especially in intercalated cells. These data support the regulation of Epo production in the kidney by the renin–angiotensin–aldosterone system (RAS).